Clinical Characteristics and Outcome of Fetal Hydronephrosis / 대한비뇨기과학회지

PURPOSE: We performed a retrospective study to determine the clinical characteristics and outcome of fetal hydronephrosis. MATERIALS AND METHODS: The records of the children diagnosed with fetal hydronephrosis between 1990 and 2001 were retrospectively analyzed. In the postnatal follow-up period, the children were followed by sequential ultrasonography and urinalysis. Diuretic renal scanning and voiding cystourethrography were performed in selected cases. The clinical characteristics and outcome were evaluated and compared to the degree of hydronephrosis. RESULTS: The study comprised 341 children with 427 dilated kidneys. Mild (Grade 1), moderate(Grade 2 or 3) and severe(Grade 4) hydronephrosis were present in 21.8%, 60.4% and 17.8% respectively. Hydronephrosis resolved spontaneously in 126(29.5%) kidneys, including 52.7% of mild and 2.6% of severe hydronephrosis. Mean interval to spontaneous resolution was 1.39(+/-1.41, SD) years. Dilatation of the renal pelvis was caused by primary ureteropelvic junction obstruction in 65.6%, multicystic kidney in 9.4%, vesicoureteral reflux in 7.0%, duplex system in 5.4%, ureterovesical junction obstruction in 4.0%, and posterior urethral valves in 3.0%. Surgery was performed in 174 kidneys, consisting of pyeloplasty in 105, ureteroneocystostomy in 23, transurethral incision in 11, and nephrectomy in 9. Most patients had initially high-grade hydronephrosis (p<0.05). CONCLUSIONS: Mild hydronephrosis appears to be relatively benign, and in most cases dilatation improves with time with surgical intervention thereby not required. On the other hand, moderate or severe hydronephrosis often RESULTS in a significantly poorer outcome and requires surgical intervention, and hence closer follow-up both antenatally and postnatally.

Challenging Cases of Renal Cell Cancers With or Without Tumor Thrombus During the Covid-19 Pandemic.

BACKGROUND/AIM: Large or bilateral multiple renal cell carcinoma (RCC) without/with tumor thrombus (TT) in the renal vein (RV) or inferior vena cava (IVC) poses a challenge to the surgeon due to the potential for massive hemorrhage, tumor thromboemboli and dialysis, and the situation is more critical due to Covid-19 pandemic. We report our experience and measures in dealing with challenging cases of large or multiple RCCs without/with TT during the ongoing Covid-19 pandemic. PATIENTS AND METHODS: Between 4/2020-10/2020, five patients underwent RCC resection with/without TT. Patients 1 and 2 had RCCs/TT in RV; Patient 3 had RCC/TT supradiaphragmatic below right atrium; Patient-4 had a 26 cm RCC; Patient-5 had multiple RCCS as part of Birt-Hogg-Dube syndrome. RESULTS: Patients were preoperatively tested negative for Covid-19. Operation times were 105, 85, 255, 200 and 247 minutes for Patients 1-5. Estimated blood loss was: 100, 50, 3,900,100 and 50 ml, respectively. Patient 3 underwent RCC resection en bloc with IVC/TT. Patients 1 and 2 underwent resections of RCC/TT in RV. Patient 4 underwent a 26 cm RCC resection. Patient 5 underwent laparoscopic bilateral radical nephrectomies. No immediate postoperative complications were reported. CONCLUSION: We successfully managed 5 challenging cases of RCCs despite the recommendations imposed by hospitals due to Covid-19 pandemic, with favorable outcomes.

Association of Surgical Delay and Overall Survival in Patients With T2 Renal Masses: Implications for Critical Clinical Decision-making During the COVID-19 Pandemic.

OBJECTIVE: To test for an association between surgical delay and overall survival (OS) for patients with T2 renal masses. Many health care systems are balancing resources to manage the current COVID-19 pandemic, which may result in surgical delay for patients with large renal masses. METHODS: Using Cox proportional hazard models, we analyzed data from the National Cancer Database for patients undergoing extirpative surgery for clinical T2N0M0 renal masses between 2004 and 2015. Study outcomes were to assess for an association between surgical delay with OS and pathologic stage. RESULTS: We identified 11,848 patients who underwent extirpative surgery for clinical T2 renal masses. Compared with patients undergoing surgery within 2 months of diagnosis, we found worse OS for patients with a surgical delay of 3-4 months (hazard ratio [HR] 1.12, 95% confidence interval [CI] 1.00-1.25) or 5-6 months (HR 1.51, 95% CI 1.19-1.91). Considering only healthy patients with Charlson Comorbidity Index = 0, worse OS was associated with surgical delay of 5-6 months (HR 1.68, 95% CI 1.21-2.34, P= .002) but not 3-4 months (HR 1.08, 95% CI 0.93-1.26, P = 309). Pathologic stage (pT or pN) was not associated with surgical delay. CONCLUSION: Prolonged surgical delay (5-6 months) for patients with T2 renal tumors appears to have a negative impact on OS while shorter surgical delay (3-4 months) was not associated with worse OS in healthy patients. The data presented in this study may help patients and providers to weigh the risk of surgical delay versus the risk of iatrogenic SARS-CoV-2 exposure during resurgent waves of the COVID-19 pandemic.